Home › Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research
 

Keywords :   


Novo Nordisk A/S (NVO) Receives Sell Rating from Zacks Investment Research

2016-01-17 15:45:50| Biotech - Topix.net

's stock had its "sell" rating reissued by Zacks Investment Research in a research report issued to clients and investors on Sunday, MarketBeat.Com reports. According to Zacks, "Novo Nordisk's third-quarter 2015 results were strong with revenues increased on the back of robust performance from Victoza and Levemir as well as significant contributions from Tresiba and Saxenda.

Tags: research rating sell investment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05Valmet Names New Vice President Services, North America
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
More »